Tag: sglt2 inhibitors

1. In this descriptive case series, 55 cases of patients with diabetes who developed Fournier gangrene while using sodium-glucose cotransporter-2 (SGLT2) inhibitors are described. 2. While neither causality nor incidence are identified in this paper, physicians prescribing SGLT2 inhibitors should be aware of the association with Fournier gangrene. Evidence Rating Level:...

1. Canagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, significantly reduced the risk of the primary composite outcome of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in patients with type 2 diabetes when compared to placebo. 2. Patients treated with canagliflozin experienced significantly higher rates of amputation, fracture, and...

1. In patients with type 2 diabetes and an estimated glomerular filtration (eGFR) rate of ≥ 30 mL per minute per 1.73 m2 of body-surface area that received empagliflozin, there was reduced incidence of new or worsening nephropathy, less incidence of doubling of creatinine and less initiation of renal-replacement...